Choose a language and wait for the translated text.
Shots:
Geron has discontinued the P-III (IMpactMF) trial of imetelstat in JAK inhibitor relapsed/refractory myelofibrosis, based on the independent DMC’s recommendation that the trial was unlikely to meet its 1EP of OS
The open-label trial randomized (2:1) 327 pts with intermediate-2 or high-risk MF to imetelstat (9.4mg/kg, IV, Q3W) or best available therapy; no new safety signals were observed, & a detailed data analysis will be shared with the scientific community later
Geron will continue to focus on growing US demand for Rytelo (imetelstat) & expanding access for eligible LR-MDS pts outside the US
Ref: GlobeNewswire | Image: Geron | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
The post Geron Discontinues P-III (IMpactMF) Trial of Imetelstat in Relapsed/Refractory Myelofibrosis appeared first on PharmaShots.
